Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1984;2(3):315-7.
doi: 10.1007/BF00175383.

Phase II study of epirubicin in advanced malignant melanoma

Phase II study of epirubicin in advanced malignant melanoma

M Lopez et al. Invest New Drugs. 1984.

Abstract

Twenty patients with advanced malignant melanoma refractory to conventional chemotherapy, were entered into a Phase II study of epirubicin, one of the new doxorubicin analogues. The drug was given at a dose of 90 mg/m2 IV every 3 weeks. One partial response and three disease stabilizations were observed. Nausea and vomiting and alopecia were common. Mild to moderate leukopenia occurred in 6 patients. Three cases of reversible ST-T changes were recorded. The observed response rate of 5% with a 39.2% probability of a true response rate greater than or equal to 10%, does not suggest that epirubicin, in the dose and schedule chosen, is active in metastatic malignant melanoma.

PubMed Disclaimer

References

    1. Cancer Treat Rep. 1979 May;63(5):915-8 - PubMed
    1. J Med Chem. 1975 Jul;18(7):703-7 - PubMed
    1. Cancer Clin Trials. 1981 Winter;4(4):433-7 - PubMed
    1. Cancer. 1981 Jan 1;47(1):207-14 - PubMed
    1. Tumori. 1982 Apr 30;68(2):105-11 - PubMed

LinkOut - more resources